Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17,850 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of metabolic pathways contributing to ER+ breast cancer disparities using a machine-learning pipeline.
Santaliz-Casiano A, Mehta D, Danciu OC, Patel H, Banks L, Zaidi A, Buckley J, Rauscher GH, Schulte L, Weller LR, Taiym D, Liko-Hazizi E, Pulliam N, Friedewald SM, Khan S, Kim JJ, Gradishar W, Hegerty S, Frasor J, Hoskins KF, Madak-Erdogan Z. Santaliz-Casiano A, et al. Among authors: khan s. Sci Rep. 2023 Jul 26;13(1):12136. doi: 10.1038/s41598-023-39215-1. Sci Rep. 2023. PMID: 37495653 Free PMC article.
Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib.
Kaklamani VG, Siziopikou K, Scholtens D, Lacouture M, Gordon J, Uthe R, Meservey C, Hansen N, Khan SA, Jeruss JS, Bethke K, Cianfrocca M, Rosen S, Von Roenn J, Wayne J, Parimi V, Jovanovic B, Gradishar W. Kaklamani VG, et al. Among authors: khan sa. Breast Cancer Res Treat. 2012 Apr;132(3):833-42. doi: 10.1007/s10549-011-1411-8. Epub 2011 Feb 27. Breast Cancer Res Treat. 2012. PMID: 21359953 Clinical Trial.
Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).
Kaklamani VG, Jeruss JS, Hughes E, Siziopikou K, Timms KM, Gutin A, Abkevich V, Sangale Z, Solimeno C, Brown KL, Jones J, Hartman AR, Meservey C, Jovanovic B, Helenowski I, Khan SA, Bethke K, Hansen N, Uthe R, Giordano S, Rosen S, Hoskins K, Von Roenn J, Jain S, Parini V, Gradishar W. Kaklamani VG, et al. Among authors: khan sa. Breast Cancer Res Treat. 2015 Jun;151(3):629-38. doi: 10.1007/s10549-015-3435-y. Epub 2015 May 26. Breast Cancer Res Treat. 2015. PMID: 26006067 Clinical Trial.
Feasibility and acceptability of intensive longitudinal data collection of activity and patient-reported outcomes during chemotherapy for breast cancer.
Solk P, Gavin K, Fanning J, Welch W, Lloyd G, Cottrell A, Nielsen A, Santa Maria CA, Gradishar W, Khan SA, Kulkarni S, Siddique J, Phillips SM. Solk P, et al. Among authors: khan sa. Qual Life Res. 2019 Dec;28(12):3333-3346. doi: 10.1007/s11136-019-02278-7. Epub 2019 Sep 6. Qual Life Res. 2019. PMID: 31493269
Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate.
Lee O, Sullivan ME, Xu Y, Rogers C, Muzzio M, Helenowski I, Shidfar A, Zeng Z, Singhal H, Jovanovic B, Hansen N, Bethke KP, Gann PH, Gradishar W, Kim JJ, Clare SE, Khan SA. Lee O, et al. Clin Cancer Res. 2020 Jan 1;26(1):25-34. doi: 10.1158/1078-0432.CCR-19-0443. Epub 2019 Sep 30. Clin Cancer Res. 2020. PMID: 31570566 Clinical Trial.
17,850 results
You have reached the last available page of results. Please see the User Guide for more information.